Literature DB >> 11856810

Emergence of macrolide resistance during treatment of pneumococcal pneumonia.

Daniel M Musher, Mark E Dowell, Virginia D Shortridge, Robert K Flamm, James H Jorgensen, Pierre Le Magueres, Kurt L Krause.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11856810     DOI： 10.1056/NEJM200202213460820

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  Resistance to macrolides and related antibiotics in Streptococcus pneumoniae.

Authors:  Roland Leclercq; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.

Authors:  Ronald N Jones; David J Farrell; Ian Morrissey
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

4.  In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

Authors:  David J Farrell; Ian Morrissey; Sarah Bakker; Sylvie Buckridge; David Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 6.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

7.  Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.

Authors:  Todd A Davies; Karen Bush; Daniel Sahm; Alan Evangelista
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

9.  In vivo emergence of high-level macrolide resistance in Streptococcus pneumoniae following a single dose of azithromycin.

Authors:  H C Smith-Vaughan; R L Marsh; P S Morris; A J Leach
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

10.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.